Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

Inclusion Criteria: * Chinese participant * Female of reproductive potential with a serum hCG level consistent with a nongravid state and agree to use 2 acceptable methods of birth control throughout the study * Body Mass Index (BMI) \>=15 and \<=30 kg/m\^2 * Anticipated or documented prolonged neutropenia and likely to last for at least 7 days due to: a) standard intensive chemotherapy, anthracycline-based or other accepted regimen (excluding any investigational agent) for a new diagnosis of acute myelogenous leukemia (AML); b)chemotherapy for AML in first relapse; or c) therapy for myelodysplastic syndromes in transformation to AML or other diagnoses of secondary AML (therapy related, antecedent hematological disorders) or chronic myelogenous leukemia in blast crisis * Free from any clinically significant disease other than the primary hematologic disease that would interfere with administration of study medication or study evaluations Exclusion Criteria: * Pregnant, intends to become pregnant during the study, or has been nursing * Mentally or legally incapacitated, has significant emotional problems, or has clinically significant psychiatric disorder over the last 5 years * Received systemic antifungal therapy (oral, intravenous, or inhaled) within 30 days of study enrollment for reasons other than antifungal prophylaxis * Known or suspected invasive or systemic fungal infection * Taken posaconazole within 10 days prior to study enrollment * Major surgery, donated or lost 1 unit of blood, or participated in another investigational study within 4 weeks prior to the study * Type 1 hypersensitivity or idiosyncratic reactions to azole agents * Significant multiple or severe allergies, or has had an anaphylactic reaction or significant intolerability to drugs or food * Moderate or severe liver dysfunction * Chronic active hepatitis, cirrhosis, Hepatocellular Carcinoma (HCC), or other hepatic disease caused by a virus * Previous electrocardiogram with a prolonged QTc interval * Prior enrollment in this study or other posaconazole studies within 90 days of study entry * Eastern Cooperative Oncology Group (ECOG) performance status was \>2 prior to induction chemotherapy for the underlying disease * Known or suspected Gilbert's disease